Celyad Oncology (XBRU:CYAD) LT-Debt-to-Total-Asset : 0.03 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Celyad Oncology's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.03.

Celyad Oncology's long-term debt to total assets ratio increased from Dec. 2021 (0.02) to Jun. 2023 (0.03). It may suggest that Celyad Oncology is progressively becoming more dependent on debt to grow their business.

Celyad Oncology LT-Debt-to-Total-Asset Historical Data

The historical data trend for Celyad Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology LT-Debt-to-Total-Asset Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.03

0.04

0.02

0.01

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.02	0.02	0.01	0.03

Celyad Oncology LT-Debt-to-Total-Asset Calculation

Celyad Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0.118	/	19.716
	=

Celyad Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	0.351	/	12.178
	=

Celyad Oncology (XBRU:CYAD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Celyad Oncology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines